Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Arcturus Therapeutics ( (ARCT) ) is now available.
On December 11, 2025, Arcturus Therapeutics announced the amicable departure of its Chief Financial Officer, Andy Sassine, effective December 31, 2025. His exit was not due to any disagreements with the company, and he will receive a severance package including salary, bonus eligibility, and stock option modifications. Joe Roberts, the company’s Controller since March 2024, was appointed as the interim principal financial officer and accounting officer. This transition is not expected to affect Mr. Roberts’ current compensation structure.
The most recent analyst rating on (ARCT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.
Spark’s Take on ARCT Stock
According to Spark, TipRanks’ AI Analyst, ARCT is a Neutral.
Arcturus Therapeutics’ overall stock score is primarily impacted by its financial performance, which is challenged by declining revenues and persistent losses. Technical analysis indicates a bearish trend, and valuation metrics are poor due to negative earnings. While there are some positive developments in clinical trials and partnerships, these are overshadowed by significant financial and regulatory challenges.
To see Spark’s full report on ARCT stock, click here.
More about Arcturus Therapeutics
Arcturus Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on the development of innovative RNA medicines for the treatment of various diseases.
Average Trading Volume: 1,328,952
Technical Sentiment Signal: Sell
Current Market Cap: $212M
For detailed information about ARCT stock, go to TipRanks’ Stock Analysis page.